Aims Abciximab has previously been shown to enhance thrombolysis and improve myocardial perfusion when combined with reduced doses of alteplase. The purpose of the reteplase phase of TIMI 14 was to evaluate the effects of abciximab when used in combination with a reduced dose of reteplase for ST-elevation myocardial infarction.
Aims Abciximab has previously been shown to enhance thrombolysis and improve myocardial perfusion when combined with reduced doses of alteplase. The purpose of the reteplase phase of TIMI 14 was to evaluate the effects of abciximab when used in combination with a reduced dose of reteplase for ST-elevation myocardial infarction.
Methods and Results
Patients (n=299) with ST-elevation myocardial infarction were treated with aspirin and randomized to a control arm with standard dose reteplase (10+10 U given 30 min apart) or abciximab (bolus of 0·25 mg . kg 1 and 12-h infusion of 0·125 g . kg 1 . min 1 ) in combination with reduced doses of reteplase (5+5 U or 10+5 U). Control patients received standard weight-adjusted heparin (bolus of 70 U . kg 1 ; infusion of 15 U . kg 1 . h 1 ), while each of the combination arms with abciximab and reduced dose reteplase received either low dose heparin (bolus of 60 U . kg 1 ; infusion of 7 U . kg 1 . h 1 ) or very low dose heparin (bolus of 30 U . kg 1 ; infusion of 4 U . kg 1 . h 1 ). The rate of TIMI 3 flow at 90 min was 70% for patients treated with 10+10 U of reteplase alone (n=87), 73% for those treated with 5+5 U of reteplase with abciximab (n=88), and 77% for those treated with 10+5 U of reteplase with abciximab (n=75). Complete (d70%) ST resolution at 90 min was seen in 56% of patients receiving a reduced dose of reteplase in combination with abciximab compared with 48% of patients receiving reteplase alone.
Introduction
Currently available regimens for pharmacological reperfusion in patients presenting with ST elevation myocardial infarction suffer from inadequate rates of restoration of normal flow in the infarct related artery and inadequate myocardial perfusion. As reported previously, abciximab in combination with reduced doses of alteplase facilitated the rate and extent of thrombolysis [1] . Among patients with TIMI 3 flow at 90 min, ST resolution was significantly greater when abciximab was administered, suggesting an additional benefit in terms of myocardial perfusion [2] . The dose of reteplase currently used in clinical practice was established by the RAPID I and RAPID II angiographic trials which reported that the double bolus regimen of 10+10 U was associated with TIMI 3 flow rates at 90 min of 63% and 60%, respectively [3, 4] . A reduced dose regimen of 10+5 U of reteplase was found in RAPID I to be associated with only a 46% rate of TIMI 3 flow at 90 min [3] . The reteplase phase of the TIMI 14 trial was designed to examine whether abciximab facilitated thrombolysis in combination with reduced doses of reteplase.
Methods
The reteplase phase of TIMI 14 was conducted between July 1998 and April 1999 at 42 enrolling centres in Germany, the United States, the United Kingdom, The Netherlands, France and Canada.
Eligibility criteria
The enrollment criteria have been described previously [1] . Patients were eligible for inclusion if they were aged between 18 and 75 years, had a qualifying episode of ischaemic discomfort of at least 30 min duration within the previous 12 h and exhibited at least 0·1 mV ST segment elevation in two contiguous leads, as reported by the enrolling clinical centre. The major exclusion criteria consisted of an ECG pattern that obscured identification of the infarct related artery, increased bleeding risk due to neurological or haematological conditions, hypertension, or prior/concomitant therapy, or general administrative criteria such as an inability to undergo cardiac catheterization.
Study protocol
All patients were given aspirin (150-325 mg orally or 250-500 mg intraveneously) and were then randomized into the treatment groups described below (Fig. 1) . The control group was treated with full dose reteplase (10+10 U) administered 30 min apart, and a standard dose of heparin consisting of a bolus of 70 U . kg 1 (maximum 4000 U) and an initial infusion of 15 U . kg 1 . h 1 (maximum 1200 U . h 1 ). The experimental groups all received an initial bolus of abciximab of 0·25 mg . kg 1 followed by a 12-h infusion of 0·125 g . kg 1 . min 1 and reduced dose reteplase (Table 1) . Abciximab was to be administered prior to or concurrent with reteplase. The two reduced-dose reteplase regimens evaluated in combination with abciximab were 5+5 U and 10+5 U of reteplase as shown in Table 1 . During the initial portion of the reteplase phase of TIMI 14, patients treated with abciximab and reduced-dose reteplase received low dose heparin using a bolus of 60 U . kg 1 81 (77) 33 (79) 39 (78) 72 (78) 234 (78) 128 (79) Female 21 (21) 9 (21) 15 (24) 24 (23) 9 (21) 11 (22) 20 (22) 65 (22) 34 (21) Race: White 90 (88) 36 (86) 59 (94) 95 (90) 34 (81) 47 (94) 81 (88) 266 (89) 149 (92) Other 12 (12) 6 (14) 4 (6) 10 (10) 8 (19) 3 (6) 11 (12) 33 (11) 13 (8) Diabetes 13 (13) 2 (5) 11 (18) 13 (12) 5 (12) 9 (8) 14 (15) 40 (13) 19 (12) Hx hypertension 29 (28) 10 (24) 21 (33) 31 (30) 12 (29) 15 (30) 27 (29) 87 (29) 43 (27) Current smoker 51 (50) 26 (62) 30 (48) 56 (53) 19 (45) 18 (36) 37 (40) 144 (48) 76 ( 
1 (2) 5 (8) 6 (6) 3 (7) 9 (18) 12 (13) 26 (9) 12 (7) MI location: Anterior 39 (38) 17 (41) 27 (43) 44 (42) 15 (36) 15 (30) 30 (33) 113 (38) 59 ( Randomization to Rx, min 16 (11, 20) 16 (13, 24) 17 (10, 29) 16 (11, 26) 24 (15, 29) 15 (11, 24) 19 (11, 28) 16 (11, 24) 16 (11, 23) Abciximab to lytic, min 53 (84) 93 (89) 37 (88) 43 (86) 80 (87) 173 ( 
Angiographic procedures
For timing the performance of coronary angiograms, time 0 was considered to be the start of administration of the first drug of the assigned reperfusion regimen. Coronary angiography of the infarct related artery was performed as soon as possible after initiation of the reperfusion regimen but in no case later than 90 min (with a window of 15 min). Standardized views and techniques of injection were used by investigators [1] .
Clinical procedures
Twelve-lead ECGs were obtained at baseline and at 90 and 180 min after reperfusion therapy. Creatine kinase (CK) and isoenzyme (CK-MB) levels were measured on admission and at 6, 12, and 24 h for the first 24 h and were repeated for episodes of recurrent ischaemic discomfort at rest d30 min in duration or following revascularization procedures during the index hospitalization. All patients were followed for clinical events during the index hospitalization and for the next 30 days.
Study end-points Efficacy
The primary angiographic efficacy end-point was the achievement of TIMI grade 3 flow at 90 min in the infarct related artery. All angiograms were evaluated at the Angiographic Core Laboratory, which was unaware of the treatment assignment, using previously established procedures for determination of TIMI flow grade and TIMI frame count [5, 6] . Patients were considered angiographically evaluable if they received the specified reperfusion regimen and had an evaluable 90-min angiogram. The angiographically evaluable cohort in patients receiving abciximab and reteplase was restricted to patients who received both abciximab and reteplase within 15 min of each other.
Clinical efficacy end-points during 30 days were analysed for all patients randomized (intention-to-treat cohort) by a Clinical Events Committee using standardized definitions. These end-points included all-cause mortality, recurrent myocardial infarction, recurrent ischaemia of d5 min, severe recurrent ischaemia requiring urgent revascularization, severe pump failure, the performance of rescue percutaneous coronary interventions, and coronary artery bypass grafting. The definitions of recurrent myocardial infarction, severe pump failure, and severe recurrent ischaemia were as previously described [1, 7, 8] .
Safety
The primary safety end-point was major haemorrhage defined as any intracranial, retroperitoneal or intraocular haemorrhage or any clinically overt haemorrhage associated with a drop in haemoglobin level d5 gm . dl
1 . An additional end-point was confirmed thrombocytopaenia (<100 000 cells . l 1 and a decrease of at least 25% from baseline). Severe thrombocytopaenia was defined as a platelet count <50 000 cells . l 1 . All patients who received any element of the assigned reperfusion regimen were included in safety analyses (safety-evaluable cohort); these events were also reviewed and classified by the Clinical Events Committee.
Two substudies were undertaken to explore the mechanism of benefit of combining abciximab with reduced doses of reteplase.
ST resolution substudy
The magnitudes of ST deviation on the baseline and 90-min ECGs were determined using previously described methods, and the percentage of ST resolution from baseline to 90 min was calculated [9] [10] [11] . ST resolution was categorized for each patient as complete (d70%), partial (30-70%), or none (<30%). Two outcome measures were prospectively defined for the comparison of different treatment regimens: median ST resolution and the proportion of patients achieving complete ST resolution. Results were stratified according to TIMI flow grade and infarct location.
Myocardial perfusion substudy
Myocardial perfusion was evaluated according to a previously described TIMI myocardial perfusion grade, an independent predictor of mortality in a multivariate analysis of data from ST-elevation myocardial infarction patients [12] . Angiograms were classified as either perfusion grade 0/1 (dye either failed to enter the microvasculature or entered but failed to exit the microvasculature) or perfusion grade 2/3 (dye entered and exited the microvasculature either with a delayed time course or normal time course).
Statistical considerations
To guide the Operations Committee in identifying promising new regimens of reduced dose reteplase and abciximab, the rates of TIMI 3 flow in each of the treatment groups were monitored using a sequential probability ratio test (SPRT) described by Wald [13] . Statistical comparisons were made by Fisher's exact test for categorical variables and the Wilcoxon rank sum test for continuous variables.
Because time from the onset of symptoms to treatment and location of the infarct related artery have been shown to influence the probability of achieving TIMI 3 flow, these two variables, along with a variable coding for whether the reperfusion regimen contained abciximab, were forced into logistic regression analyses assessing the likelihood of developing TIMI 3 flow at 90 min [14] . The same logistic regression models were used to assess the likelihood of achieving complete (d70%) ST-segment resolution at 90 min.
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Due to the exploratory nature of the comparisons in the trial, nominal P values, without adjustment for multiple comparisons, were taken as an indicator of the statistical significance of comparisons between groups or trends among groups.
Results
A total of 299 consecutive patients were enrolled in the reteplase portion of TIMI 14. Baseline characteristics are shown in Table 1 .
Impact of abciximab on epicardial flow
Of the 299 patients, 250 (84%) were considered angiographically evaluable at 90 min. The reasons for exclusion from the angiographically evaluable cohort at 90 min were failure to receive the reperfusion regimen as specified in the protocol (n=14 [5%]) and lack of a suitable angiogram due either to absence of angiography for clinical reasons, performance of the angiogram more than 15 min outside the 90-min timeframe or technically inadequate imaging (n=35 [12%]). Eighty-three patients (28%) were considered angiographically evaluable at 60 min.
Patients treated with 10+10 U of reteplase alone (n=87) achieved a 70% rate of TIMI 3 flow at 90 min ( Table 2 ). The rate of TIMI 3 flow at 90 min was 73% among the 88 patients in the 5+5 U of reteplase plus abciximab group and 77% among the 75 patients in the 10+5 U of reteplase plus abciximab group (Table 2) . No clinically important, directionally consistent difference in TIMI 3 flow rates was observed at 90 min when the reduced dose reteplase plus abciximab groups were analysed according to whether they received low dose or very low dose heparin (Table 2) .
There tended to be differences among the treatment groups in the distribution of the infarct related artery and time from onset of symptoms to treatment with the assigned reperfusion regimen (see Table 2 ). While the likelihood of developing TIMI 3 flow at 90 min tended to be lower if the left anterior descending artery was the infarct related artery and decreased progressively as the delay in treatment increased, use of a regimen containing abciximab tended to be associated with an increase in the odds of developing TIMI 3 flow (see Table 4 ). 
Impact of abciximab on ST resolution
One hundred and sixty-two patients had interpretable baseline and 90-min ECGs and were enrolled in the ST resolution substudy. No significant differences in baseline characteristics were noted between the cohort of patients in the ST resolution substudy and the full cohort of patients in the reteplase phase of TIMI 14 ( Table 1) . The proportion of patients achieving complete ST resolution was 48% in the reteplase control group versus 44% in the 5+5 U of reteplase plus abciximab group and 68% in the 10+5 U of reteplase plus abciximab group (P=0·05 versus reteplase control) ( Table 3) . In an analysis restricted to patients with TIMI grade 3 flow at 90 min, the proportion of patients achieving complete ST resolution was 55% in the reteplase control group versus 51% in the 5+5 U of reteplase plus abciximab group and 78% in the 10+5 U of reteplase plus abciximab group (P<0·05 versus reteplase control).
It is important to note that imbalances in the distribution of the location of infarction were also seen in the ECG substudy cohort. The proportion of patients with anterior myocardial infarction was 37% in the 10+10 U of reteplase control group, 53% in the 5+5 U of reteplase plus abciximab group, and 28% in the 10+5 U of reteplase plus abciximab group. The multivariate analysis of the ECG data is shown at the bottom of Table 4 . The odds of developing complete ST resolution at 90 min was significantly lower if the left arterior descending artery was the infarct artery. Patients treated 
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later tended to have a lower chance of achieving complete ST resolution. Use of a reperfusion regimen containing abciximab tended to be associated with a greater chance of achieving complete ST resolution (Table 4) .
Measurement of the TIMI Myocardial Perfusion Grade was introduced after the trial was underway and therefore the results were available in the subset of the final consecutive 99 patients with evaluable angiograms analysed in the Angiographic Core Laboratory. Of the 33 patients in the 10+10 U of reteplase control group, 14 (42%) had perfusion grade 2/3. Of the 66 patients receiving a regimen containing abciximab and a reduced dose of reteplase (either 5+5 U or 10+5 U), 40 (61%) had perfusion grade 2/3 (P=0·08 compared with control group). In an analysis restricted to 73 patients with TIMI 3 flow, a perfusion grade of 2/3 was observed in 11 (48%) patients in the reteplase control group and 31 (62%) patients receiving a regimen of reduced dose reteplase plus abciximab (Fig. 2) .
Safety observations and other clinical events in reteplase phase
Safety observations along with other clinical events are summarized in Table 5 . The overall rate of major haemorrhage was 6%; the majority of events were major bleeds at instrumented sites. The overall rates for intracranial haemorrhage, mortality, recurrent myocardial infarction, development of severe pump failure, and revascularization for severe recurrent ischaemia were 1·3%, 4%, 2%, 2% and 22%, respectively. No statistically significant differences in the events noted above were Major haemorrhage Total 4 (4) 1 (2) 3 (5) 4 (4) 6 (14) 5 (10) 11 (12) 19 (6) Spontaneous (17) 1 (2) 4 (4) 2 (5) 1 (2) 3 (3) 11 (4) Severe thrombocytopaenia 1 (1)
Data are shown as n (%) for dichotomous variables and median (25, 75 th percentile) for continuous variables. ICH=intra-cranial haemorrhage.
seen across the dose groups. However, the patients receiving 10+5 U of reteplase plus abciximab had a numerically higher mortality rate as well as higher rates of haemorrhagic events compared with both the 10+10 U of reteplase control group and the 5+5 U of reteplase plus abciximab groups (Table 5) .
Discussion
The reteplase phase of TIMI 14 supports the hypothesis that glycoprotein IIb/IIIa inhibition with abciximab facilitates reperfusion of thrombotically occluded coronary arteries. In earlier angiographic trials, the 10+10 U regimen of reteplase was associated with a higher rate of TIMI 3 flow at 90 min than a reduced dose regimen of 10+5 U [3, 4] . As shown in Fig. 3 , abciximab combined with reduced doses of reteplase was associated with TIMI 3 flow rates at least comparable full dose reteplase, and appeared to be higher than reported previously for 10+5 U of reteplase monotherapy. Despite the limitations of comparing angiographic results from different trials and Angiographic Core Laboratories, the magnitude of the difference suggests that this observation reflects a true difference. Furthermore, the multivariate analysis suggests that, after adjusting for infarct artery location and time to treatment, use of abciximab in combination with reduced doses of reteplase tends to increase the odds of achieving TIMI 3 flow.
It is interesting that the 90-min TIMI 3 flow rates in the combination arms of the alteplase and reteplase phases of TIMI 14 are similar (73-77%) underscoring the observation that abciximab enhances thrombolysis. This is particularly noteworthy since, as previously reported in a substudy from TIMI 14, platelet activation and aggregation are heightened in the setting of thrombolysis for acute myocardial infarction [15] . Despite enhanced platelet activity, the dose of abciximab used in TIMI 14 was associated with >80% inhibition of platelet aggregation to 20 M ADP, a value comparable to that seen in a more elective setting such as percutaneous coronary intervention [15] . In addition to diminishing the mass of platelet aggregates, abciximab weakens the clot structure and permits greater penetration by the thrombolytic agent into the clot [16] [17] [18] [19] [20] [21] . Additional important observations with respect to myocardial perfusion are found in the ST resolution and TIMI Myocardial Perfusion Grade analyses [22] . Despite restoration of normal flow in the infarct related epicardial coronary artery, many patients suffer from inadequate myocardial perfusion as evidenced by the microvascular 'no reflow' pattern. This finding is associated with poor recovery of left ventricular function [23] . Microvascular obstruction is the leading hypothesis for the no reflow phenomenon. Recent studies have shown that persistent ST elevation after primary percutaneous intervention in acute myocardial infarction is associated with no reflow seen on myocardial contrast echo and is an indicator of increased risk for cardiovascular morbidity and mortality [24, 25] . We have previously reported that abciximab in combination with reduced dose alteplase improved both epicardial flow (TIMI 3 flow) and myocardial perfusion as reflected in a greater degree of ST-segment resolution [2] . The trend towards improved ST resolution when abciximab was combined with reduced dose reteplase is directionally consistent with the alteplase phase of the trial [2] . Additional support for a direct effect of abciximab on the myocardial microcirculation is provided by the improvements in TIMI Myocardial Perfusion Grade observed in the reteplase phase of the trial (Fig. 2 ) [12, 22] .
Clinical implications
The findings reported here extend our earlier obser vations on abciximab in several ways. Reduced doses of reteplase when administered in combination with abciximab were associated with higher TIMI 3 flow rates than reported previously without abciximab and were at least as high as those for full dose reteplase alone. The facilitation of thrombolysis with reteplase coupled with earlier observations with alteplase, supports the notion that there is an independent effect of abciximab on the thrombus in the infarct artery. Finally, the benefits of abciximab extend beyond facilitation of thrombolysis in the epicardial infarct artery to an improvement in myocardial perfusion. Although there was no important difference in the rate of TIMI 3 flow at 90 min with the 5+5 U of reteplase plus abciximab regimen compared with the 10+5 U of reteplase plus abciximab regimen, the latter was associated with higher rates of haemorrhagic events. These factors may have been taken into consideration when designing the GUSTO IV myocardial infarction study, a phase III trial comparing 10+10 U of reteplase alone versus 5+5 U of 
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reteplase plus abciximab with respect to 30-day mortality in patients with ST-elevation myocardial infarction.
